Last Updated: November 16, 2026

Investigational Drug Information for SAR442168

« Back to Dashboard


What is the drug development status for SAR442168?

SAR442168 is an investigational drug.

There have been 10 clinical trials for SAR442168. The most recent clinical trial was a Phase 2 trial, which was initiated on June 30th 2020.

The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Multiple Sclerosis, Chronic Progressive. The leading clinical trial sponsors are Sanofi and [disabled in preview].

There are sixteen US patents protecting this investigational drug and twenty-six international patents.

Recent Clinical Trials for SAR442168
TitleSponsorPhase
Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia GravisSanofiPhase 3
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)SanofiPhase 3
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)SanofiPhase 3

See all SAR442168 clinical trials

Clinical Trial Summary for SAR442168

Top disease conditions for SAR442168
Top clinical trial sponsors for SAR442168

See all SAR442168 clinical trials

US Patents for SAR442168

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SAR442168 ⤷  Start Trial NLRP3 inflammasome inhibitors Novartis AG ⤷  Start Trial
SAR442168 ⤷  Start Trial Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof Novartis AG , Aurigene Pharmaceutical Services Ltd ⤷  Start Trial
SAR442168 ⤷  Start Trial Methods for assessing risk of developing a viral disease using a genetic test Assistance Publique Hopitaux de Paris APHP , Institut National de la Sante et de la Recherche Medicale INSERM , Universite Paris Saclay , PML Screening LLC ⤷  Start Trial
SAR442168 ⤷  Start Trial Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (RMS) Principia Biopharma Inc ⤷  Start Trial
SAR442168 ⤷  Start Trial Crystalline form of Tolebrutinib Principia Biopharma Inc ⤷  Start Trial
SAR442168 ⤷  Start Trial Methods for assessing risk of developing a viral disease using a genetic test Assistance Publique Hopitaux de Paris APHP , Institut National de la Sante et de la Recherche Medicale INSERM , Universite Paris Saclay , PML Screening LLC ⤷  Start Trial
SAR442168 ⤷  Start Trial Crystal and amorphous form of tolebrutinib, preparation method therefor, and use thereof Hangzhou Solipharma Co Ltd ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SAR442168

Drugname Country Document Number Estimated Expiration Related US Patent
SAR442168 Argentina AR104865 2035-06-03 ⤷  Start Trial
SAR442168 Australia AU2016270973 2035-06-03 ⤷  Start Trial
SAR442168 Australia AU2020203447 2035-06-03 ⤷  Start Trial
SAR442168 Brazil BR112017025850 2035-06-03 ⤷  Start Trial
SAR442168 Canada CA2987335 2035-06-03 ⤷  Start Trial
SAR442168 Chile CL2017003073 2035-06-03 ⤷  Start Trial
SAR442168 Chile CL2019002150 2035-06-03 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

SAR442168 (Tolebrutinib) Development Update and Market Projection

Last updated: October 11, 2026

SAR442168, now known as tolebrutinib, is Sanofi’s investigational, brain-penetrant, irreversible Bruton's tyrosine kinase (BTK) inhibitor for multiple sclerosis. Its commercial value depends primarily on whether it can become the first disease-modifying therapy with a meaningful effect in non-relapsing secondary progressive multiple sclerosis (nrSPMS). The development program has faced liver-safety restrictions and mixed efficacy results across disease settings.

The central investment conclusion is that tolebrutinib has a differentiated opportunity in progressive MS, but its regulatory and commercial profile is narrower than an all-spectrum MS product. A successful launch could support peak annual sales of approximately $1.5 billion to $3.0 billion. A restricted label or failure in primary progressive MS would reduce that range materially.

What is SAR442168 and how does tolebrutinib work?

Tolebrutinib is an oral, covalent BTK inhibitor designed to cross the blood-brain barrier. BTK inhibition affects B-cell receptor signaling and myeloid-cell activation, mechanisms implicated in inflammatory activity within the central nervous system.

Unlike many established MS therapies, tolebrutinib is being developed to address compartmentalized inflammation associated with disability progression, particularly in progressive MS. The program is not positioned as a simple replacement for anti-CD20 antibodies or oral relapsing-MS therapies.

Key development characteristics

Attribute SAR442168 / tolebrutinib
Generic name Tolebrutinib
Developer Sanofi
Originator Principia Biopharma
Acquisition Sanofi acquired Principia in 2020
Mechanism Irreversible, brain-penetrant BTK inhibition
Dosage form Oral tablet, once daily in clinical development
Lead indication Non-relapsing secondary progressive MS
Other indications Relapsing MS and primary progressive MS
Regulatory status Investigational; not approved
Orange Book status No approved listing
Biosimilar relevance Not applicable; this is a small-molecule drug

Sanofi acquired Principia for approximately $3.7 billion in 2020, gaining full control of the BTK inhibitor portfolio, including tolebrutinib. [1]

What is the clinical development status of tolebrutinib?

The Phase 3 program includes HERCULES in nrSPMS, GEMINI 1 and GEMINI 2 in relapsing MS, and PERSEUS in primary progressive MS.

HERCULES: the main commercial value driver

HERCULES evaluated tolebrutinib in patients with nrSPMS who had no recent clinical relapses but remained at risk of disability progression. Sanofi reported that the trial met its primary endpoint, with tolebrutinib reducing the risk of confirmed disability progression by approximately 31% compared with placebo. [2]

The result is strategically important because nrSPMS has limited treatment options and a high unmet need. A positive disability-progression result in this population provides a clearer differentiation than relapse reduction in the highly competitive relapsing-MS segment.

GEMINI 1 and GEMINI 2: mixed positioning in relapsing MS

GEMINI 1 and GEMINI 2 compared tolebrutinib with teriflunomide in relapsing MS. The studies did not deliver the broad efficacy outcome required to establish tolebrutinib as a leading relapsing-MS therapy. This limits the product’s ability to compete directly across the entire MS market.

The commercial implication is significant. A label focused on progressive MS would produce a smaller patient population than a label spanning relapsing and progressive disease. It would also reduce the potential for treatment switching from high-volume products such as ocrelizumab, ofatumumab, natalizumab and cladribine.

PERSEUS: primary progressive MS remains an upside catalyst

PERSEUS is evaluating tolebrutinib in primary progressive MS. The trial is relevant because progressive MS remains under-served, but the regulatory and commercial outcome depends on a measurable effect on disability progression.

A successful PERSEUS result could expand the addressable population and improve payer positioning. A negative result would not necessarily eliminate the nrSPMS opportunity, but it would reduce the case for broad progressive-MS adoption.

What liver-safety issues affect the FDA status of SAR442168?

Tolebrutinib’s development has been affected by drug-induced liver injury, including serious liver events. The FDA placed a partial clinical hold on parts of the program in 2022 after liver-safety concerns emerged. Sanofi subsequently implemented additional monitoring and exclusion criteria. [3]

The liver issue has three commercial consequences:

  1. It raises the probability of a restricted label.
  2. It may require frequent liver-function monitoring after initiation.
  3. It could reduce use in patients with existing liver disease or concomitant hepatotoxic medicines.

The safety profile is more consequential for tolebrutinib than for many specialty drugs because MS patients have multiple chronic treatment options. Payers and neurologists may favor therapies with longer-established safety records unless the product demonstrates a clear benefit in disability progression.

As of the latest public development disclosures covered here, tolebrutinib had not received FDA approval, a biologics license, or a commercial launch authorization. No FDA exclusivity period had been established.

What is the Orange Book status of tolebrutinib?

Tolebrutinib has no Orange Book listing because it is not an FDA-approved drug. It therefore has no approved product reference listed under an innovator name and no current Paragraph IV litigation associated with an approved NDA.

The future patent and regulatory framework would likely include:

  • New chemical entity exclusivity, if the FDA approves the active ingredient and statutory criteria are satisfied.
  • Patent protection for the active compound.
  • Formulation or solid-state patents.
  • Method-of-use patents directed to progressive MS and disability progression.
  • Potential patent-term extension based on regulatory review time.
  • Pediatric exclusivity only if qualifying pediatric requirements are completed.

What patents protect SAR442168?

The tolebrutinib estate originated with Principia and is expected to include composition-of-matter, pharmaceutical composition and therapeutic-use patent families. Public patent-family records indicate that core protection is generally directed into the mid-2030s, before any patent-term extension or pediatric extension.

The highest-value claims are likely to be:

Patent category Commercial relevance
Composition of matter Protects the tolebrutinib molecule and related compounds
Salt, crystal and solid-state claims Protects the marketed active form and manufacturing properties
Pharmaceutical composition Covers tablet formulations and excipient combinations
Method of treatment Covers use in progressive or relapsing MS
Dosing and patient-selection claims May protect liver-monitoring protocols or selected patient populations
Manufacturing processes Can raise scale-up and purity barriers

The core composition patent is more important than later method-of-use patents because it can block generic launch across indications. Method patents could still delay or complicate a generic launch where the patented indication remains commercially important.

Patent expiry should not be treated as a single date. The relevant timeline will depend on the earliest effective priority date, issued patent claims, patent-term adjustment, patent-term extension and any terminal disclaimers. No approved-product Orange Book patent date exists at this stage.

When could tolebrutinib lose exclusivity?

A practical exclusivity framework is as follows:

Event Estimated timing or status
Potential regulatory filing Dependent on completion of Phase 3 and regulatory interactions
Potential FDA approval Not established
New chemical entity exclusivity Potentially five years after approval
Core patent protection Expected to extend into the mid-2030s based on public patent-family timing
Potential PTE Could add up to five years, subject to statutory limits
First generic challenge More likely several years before core patent expiry
Generic launch Dependent on Paragraph IV litigation, settlement and enforceable claims

Paragraph IV challenges would most likely target weak or narrow method-of-use claims first. A generic manufacturer could file an abbreviated new drug application with a certification that it does not seek approval for patented progressive-MS uses, while still seeking approval for unpatented uses. Sanofi’s ability to rely on a strong composition patent would determine whether such a strategy creates a practical launch risk.

Which companies are challenging tolebrutinib?

No public generic or biosimilar challenger is associated with tolebrutinib because the drug has not been approved. The competitive threat comes from marketed MS products and other BTK inhibitors in development.

Main competitive products

Product Company Key competitive position
Ocrevus Roche Established high-efficacy therapy for relapsing and primary progressive MS
Kesimpta Novartis High-growth self-administered anti-CD20 therapy for relapsing MS
Briumvi TG Therapeutics Anti-CD20 therapy for relapsing MS
Tysabri Biogen High-efficacy therapy with long commercial experience
Mavenclad Merck KGaA Immune-reconstitution therapy for relapsing MS
Ponvory and Zeposia Johnson & Johnson/Bristol Myers Squibb Oral S1P therapies
Evobrutinib Merck KGaA BTK competitor; development setbacks reduced its threat
Fenebrutinib Roche BTK competitor with ongoing MS development

Ocrevus is the most important benchmark in progressive MS. Tolebrutinib would need to show a clinically credible effect on disability progression and maintain a manageable liver-safety profile to displace or complement established anti-CD20 treatment.

What market size and revenue could tolebrutinib achieve?

The addressable market depends on the approved label rather than the total MS population.

Scenario-based peak sales projection

Scenario Assumed label Estimated peak sales
Low Restricted nrSPMS label, intensive monitoring, limited uptake $0.6 billion-$1.2 billion
Base nrSPMS approval with durable disability-progression data and broader payer coverage $1.5 billion-$2.2 billion
High nrSPMS plus PPMS approval, favorable safety management and selected relapsing-MS use $2.5 billion-$3.0 billion

The base case assumes a specialty-net annual price of approximately $70,000 to $90,000, penetration of 10% to 15% of treated eligible progressive-MS patients, and increasing use in patients with confirmed progression despite standard therapy.

Revenue would ramp gradually because physicians typically require real-world evidence for a new MS mechanism, particularly when liver monitoring is required. A plausible launch profile would be:

Year after launch Base-case revenue
Year 1 $100 million-$250 million
Year 2 $350 million-$650 million
Year 3 $750 million-$1.2 billion
Year 4 $1.2 billion-$1.7 billion
Year 5 $1.6 billion-$2.2 billion

These estimates exclude royalties, regional licensing economics and potential price concessions. They also assume approval in the United States and Europe with a label covering at least nrSPMS.

What licensing deals affect SAR442168?

Sanofi acquired Principia Biopharma and obtained control of tolebrutinib through that transaction. No separate late-stage commercialization partnership is required for the principal U.S. and European markets based on the public development structure.

The acquisition reduces licensing uncertainty but concentrates clinical, regulatory and commercial risk at Sanofi. Regional partnering could become more likely in Japan, China or other markets where local regulatory execution and reimbursement access are important.

What generic entry risks exist for tolebrutinib?

Generic entry risk is low before approval and launch but will increase as the core composition patent approaches expiry. The principal risks are:

  • A successful Paragraph IV challenge to the core compound patent.
  • An at-risk launch after an adverse district-court decision.
  • A non-infringing generic product using a different salt or formulation.
  • Carve-outs from patented progressive-MS indications.
  • Weaknesses in later-issued formulation or method patents.
  • Patent settlements that permit an authorized or independent generic launch before full expiry.

A broad, valid composition patent would provide the strongest barrier. Method-of-use patents alone would offer less protection because generic applicants can pursue indication carve-outs.

How strong is the patent estate and commercial case?

The patent estate appears commercially useful but cannot be fully valued until the FDA-approved product, Orange Book listing and final issued claims are known. The strongest commercial asset is the disease-modifying opportunity in nrSPMS, not relapsing-MS volume.

Tolebrutinib’s risk-adjusted value is shaped by four factors:

  1. HERCULES supports a differentiated progressive-MS thesis.
  2. GEMINI limits the case for broad relapsing-MS market share.
  3. Liver injury creates regulatory and prescribing friction.
  4. Mid-2030s patent protection could support a meaningful launch window if approval occurs before the end of the decade.

Key Takeaways

  • SAR442168 is tolebrutinib, Sanofi’s oral, brain-penetrant BTK inhibitor.
  • HERCULES is the primary value driver after a reported reduction in confirmed disability progression in nrSPMS.
  • GEMINI results weaken the case for broad relapsing-MS penetration.
  • Liver toxicity remains the principal regulatory and commercial risk.
  • Tolebrutinib has no FDA approval, Orange Book listing, approved exclusivity period or known generic challenger.
  • Public patent-family timing points to core protection generally extending into the mid-2030s, subject to issued claims and patent-term adjustments.
  • Base-case peak sales are approximately $1.5 billion to $2.2 billion.
  • A PPMS approval could lift peak sales toward $3.0 billion; a restricted nrSPMS label could limit sales to about $1.2 billion.

FAQs

Is SAR442168 the same drug as tolebrutinib?

Yes. SAR442168 is the development code for tolebrutinib, an investigational BTK inhibitor developed by Sanofi after its acquisition of Principia Biopharma.

Is tolebrutinib approved for multiple sclerosis?

No. It remains investigational and has no approved FDA label or commercial Orange Book entry.

What is the main indication for tolebrutinib?

The lead commercial indication is non-relapsing secondary progressive multiple sclerosis, where HERCULES evaluated confirmed disability progression.

Does tolebrutinib compete with Ocrevus?

Yes. The products could compete in progressive MS, although Ocrevus has an established approval and commercial base. Tolebrutinib’s differentiation would depend on its effect on disability progression and its liver-safety profile.

When could a generic version of tolebrutinib launch?

A generic launch is unlikely before the expiration of core composition protection, which public patent-family timing places generally in the mid-2030s. Earlier entry could occur through a successful Paragraph IV challenge or a negotiated settlement.

References

  1. Sanofi. (2020). Sanofi to acquire Principia Biopharma, expanding its immunology pipeline. Sanofi press release.

  2. Sanofi. (2024). Sanofi reports positive Phase 3 HERCULES results for tolebrutinib in non-relapsing secondary progressive multiple sclerosis. Sanofi press release.

  3. U.S. Food and Drug Administration. (2022). Clinical hold and safety communications relating to tolebrutinib clinical development. FDA regulatory communications.

  4. ClinicalTrials.gov. (n.d.). Study of tolebrutinib in participants with non-relapsing secondary progressive multiple sclerosis: HERCULES. National Library of Medicine.

  5. ClinicalTrials.gov. (n.d.). Studies of tolebrutinib in relapsing multiple sclerosis and primary progressive multiple sclerosis. National Library of Medicine.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.